We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+17.58%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$2.97B
AUM Growth
+$703M
Cap. Flow
+$803M
Cap. Flow %
27.04%
Top 10 Hldgs %
34.36%
Holding
350
New
119
Increased
64
Reduced
60
Closed
59

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$25.3M
2
LLY icon
Eli Lilly
LLY
+$24.5M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$18.4M
4
XFOR icon
X4 Pharmaceuticals
XFOR
+$15.7M
5
MGNX icon
MacroGenics
MGNX
+$12.2M

Top Sells

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$21.4M
2
KALV
KalVista Pharmaceuticals
KALV
+$20.2M
3
BMY icon
Bristol-Myers Squibb
BMY
+$17.9M
4
CLDX icon
Celldex Therapeutics
CLDX
+$17.7M
5
PRTA icon
Prothena Corp
PRTA
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 22.28%
2 Consumer Staples 0.05%
3 Financials 0.03%
4 Industrials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIR icon
51
PUT
Vir Biotechnology
VIR
$1.46B
$12.8M 0.43%
250,000
-18,000
-7% -$970K
XLU icon
52
CALL
State Street Utilities Select Sector SPDR ETF
XLU
$22.8B
$12.8M 0.43%
+400,000
New +$12.4M
NVAX icon
53
CALL
Novavax
NVAX
$1.2B
$12.7M 0.43%
+70,000
New +$13.9M
TXG icon
54
PUT
10x Genomics
TXG
$6B
$12.7M 0.43%
+70,000
New +$12.1M
CLDX icon
55
Celldex Therapeutics
CLDX
$2.99B
$12.3M 0.41%
596,290
-768,700
-56% -$17.7M
TVRD
56
Tvardi Therapeutics
TVRD
$19.7M
$12.1M 0.41%
15,515
+7,917
+104% +$5.42M
NBP
57
NovaBridge Biosciences American Depositary Shares
NBP
$185M
$12.1M 0.41%
250,000
+100,000
+67% +$5.43M
BPMC
58
PUT
DELISTED
Blueprint Medicines
BPMC
$11.7M 0.39%
120,000
– –
XENE icon
59
Xenon Pharmaceuticals
XENE
$6.06B
$11.5M 0.39%
640,576
+417,403
+187% +$7.07M
ITCI
60
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$11.2M 0.38%
330,989
+50,000
+18% +$1.73M
PRTA icon
61
Prothena Corp
PRTA
$425M
$11M 0.37%
437,430
-749,270
-63% -$14.1M
MIST icon
62
Milestone Pharmaceuticals
MIST
$138M
$10.6M 0.36%
1,836,545
– –
RETA
63
PUT
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$10.5M 0.35%
104,900
-61,700
-37% -$7.2M
KYNB
64
PUT
Kyntra Bio
KYNB
$27.2M
$10.4M 0.35%
12,000
+1,924
+19% +$2.05M
ARNA
65
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
$10.4M 0.35%
150,000
+107,500
+253% +$8.27M
CLDX icon
66
CALL
Celldex Therapeutics
CLDX
$2.99B
$10.4M 0.35%
503,500
+103,500
+26% +$2.38M
CCXI
67
CALL
DELISTED
ChemoCentryx, Inc.
CCXI
$10.2M 0.34%
+200,000
New +$12M
TARA icon
68
Protara Therapeutics
TARA
$220M
$10.2M 0.34%
649,542
– –
RLMD icon
69
Relmada Therapeutics
RLMD
$557M
$10.2M 0.34%
+290,207
New +$10.2M
PCVX icon
70
Vaxcyte
PCVX
$7.81B
$9.9M 0.33%
501,110
+225,000
+81% +$5.66M
GOSS icon
71
Gossamer Bio
GOSS
$82.9M
$9.7M 0.33%
1,048,383
– –
ARGX icon
72
PUT
argenx
ARGX
$53.4B
$9.5M 0.32%
34,500
-167,000
-83% -$52.8M
IRON icon
73
Disc Medicine
IRON
$2.94B
$9.27M 0.31%
+22,813
New +$10.2M
CVAC
74
CALL
DELISTED
CureVac
CVAC
$9.14M 0.31%
+100,000
New +$9.7M
LYRA
75
DELISTED
LYRA THERAPEUTICS INC
LYRA
$9.05M 0.3%
15,615
-692
-4% -$432K
1 2
3
4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Ikarian Capital held 350 positions worth $2.97B, up 31% from $2.27B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Ikarian Capital deployed $803M of net new capital in Q1 2021, opening 119 new positions and adding to 64 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 1,336,412 shares worth $4.57M.

By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 24% a quarter earlier, followed by Consumer Staples and Financials.

On the sell side, the largest reduction was Morphic Holding, Inc. Common Stock, an estimated $21.4M trimmed.

  • Ikarian Capital's largest Q1 2021 buy was Odonate Therapeutics, Inc. Common Stock: 1,336,412 shares worth $4.57M.
  • Ikarian Capital added most to X4 Pharmaceuticals in Q1 2021, an estimated $15.7M increase.
  • Ikarian Capital's biggest Q1 2021 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $21.4M.
  • Ikarian Capital fully exited Bristol-Myers Squibb in Q1 2021, selling an estimated $17.9M.
  • Ikarian Capital's ten largest holdings make up 34% of its $2.97B portfolio in Q1 2021.
  • Ikarian Capital opened 119 new positions and closed 59 in Q1 2021.
  • Ikarian Capital's portfolio value rose 31% quarter-over-quarter to $2.97B.

Based on Ikarian Capital's 13F filing for Q1 2021, filed 17 May 2021.